Patrick Mahaffy, Clovis CEO (Kathryn Scott Osler/The Denver Post via Getty Images)
June 17, 2022 01:41 PM EDT
R&D

Tee­ter­ing on the brink, Clo­vis aban­dons an ear­ly ap­proval for Rubra­ca

John Carroll

Editor & Founder

A long suf­fer­ing Clo­vis On­col­o­gy $CLVS has re­turned with an­oth­er set­back to re­port.

The Boul­der-based Clo­vis is us­ing the SEC once again to com­mu­ni­cate with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times